Aims Sulfonylureas may interfere with 'ischaemic preconditioning' and worsen the prognosis in diabetic patients with acute myocardial infarction.
Introduction
In 1970, the University Group Diabetes Program (UGDP) study [1] provided evidence from a prospective treatment study, that overall and cardiovascular mortality over an 8-year period was higher in Type 2 diabetic patients randomized to sulfonylurea (tolbutamide) [1] and biguanide (phenformin) [2] treatment, despite beneficial effects of both agents on plasma glucose concentrations. These results have been widely disputed [3] [4] [5] , but have not been refuted by any large-scale treatment study until today. Sulfonylurea compounds continue to be used in the treatment of Type 2 diabetes. In Germany, approximately 33% of diabetic patients are treated with sulfonylureas, notably with glibenclamide (glyburide), which has a market share of 90% [6] . Sulfonylurea compounds like glibenclamide close ATP-dependent K + -channels in B cells (islet of Langerhans), causing the augmentation of glucose-induced insulin secretion [7] , but also in myocardial as well as vascular cells [8, 9] . Recently, renewed discussion has focused on cardiovascular effects of sulfonylurea compounds [10] [11] [12] , which (1) reduce the protective effect of ischaemic preconditioning, thereby making myocardium more vulnerable to repeated ischaemic episodes [13] [14] [15] [16] , (2) interact with the regulation of coronary perfusion favouring reduced basal perfusion and diminished increments under stress conditions [11] , and (3) reduce electric instability/vulnerability [17] [18] [19] . Given this theoretical background, credit has been given to the clinical results of the UGDP study [10] . One hypothesis that can be deduced from these findings is that interference of sulfonylureas with cardiac sulfonylurea receptors may, by interfering with the protective ischaemic preconditioning, lead to greater myocardial necroses and, thereby, a worse clinical outcome in those Type 2 diabetic patients treated with, for example, glibenclamide.
Greater mortality after myocardial infarction in diabetic vs non-diabetic patients is a well-recognized problem attention to the effects of different antidiabetic treatments on the short-and long-term prognosis after acute myocardial infarction in diabetic patients. A recent study suggested that 'tablet treatment' was associated with a significantly greater 28 day-mortality, but did not specify the pharmacological agents used (sulfonylureas, metformin, or acarbose) [23] . Similar results have been reported by Soler et al. [24] , but this is not supported by other studies [25] . Therefore, it appeared necessary to study early mortality in Type 2 diabetic patients suffering acute myocardial infarction in comparison to non-diabetic controls and to take into account the medication, especially the prescription and use of sulfonylurea compounds, in diabetic patients. To estimate the size of myocardial infarcts, the increments in creatine kinase (and myocardium-specific creatine kinase MB ) activity were also evaluated [26, 27] . Preliminary data have been published in abstract form [28] .
Methods

Patients
All patients admitted to the Department of Medicine of the Ruhr-University, Knappschafts-Krankenhaus, Bochum (Langendreer), between 1 January 1991, and 30 June 1997, in whom the clinical diagnosis of acute myocardial was made, were evaluated retrospectively. The patients were identified from two sources. The intensive care unit's documents stating the principal diagnosis (in words) and the ICD code characterizing the patients' main diagnosis at admission. Hospital charts from all patients with myocardial infarction or with ICD code 413 were screened. The clinical diagnosis made during the hospital stay was not questioned. Patients were excluded from the present analysis if the diagnosis was not acute myocardial infarction, if no information about the diabetic state could be obtained, or if diabetes mellitus was known, but there was no information about the antidiabetic treatment. If necessary, additional information was sought by means of a telephone interview from the patients themselves (in survivors), from their families, or from their primary care physicians. Based on the criteria mentioned above, five patients with acute myocardial infarction (>1% of the 607 patients screened) had to be excluded from the analysis.
The diagnosis of diabetes mellitus was based on the patients' history (i.e. a diagnosis of diabetes mellitus had been made on a previous occasion), and especially on the type of diet and or medication that had been prescribed (insulin, sulfonylurea drugs, metformin, or acarbose). Type 1 diabetes was assumed if insulin treatment was initiated within 6 months of the time of diagnosis, or if a history of ketoacidosis was documented. There were no equivocal cases that did not allow a clear differential diagnosis of Type 1 vs Type 2 diabetes. Eight patients with Type 1 diabetes were excluded from the present analysis. There were no patients with other forms of diabetes (e.g. secondary forms). In a considerable number of cases, diabetes was diagnosed on the occasion of the myocardial infarction ('newly diagnosed diabetes'). The revised American Diabetes Association/World Health Organization criteria [29] All creatine kinase activities (including creatine kinase MB ) measured in each patient were recorded. As a rule, patients remained on the intensive care unit until creatine kinase MB values were normalized. Creatine kinase (creatine kinase MB ) activities were determined twice daily at 12 h intervals. A baseline creatine kinase activity of 20 U . l 1 and a baseline creatine kinase MB activity of 2 U . l 1 were assumed (the approximate mean creatine kinase and creatine kinase MB activities in subjects not suffering myocardial infarction in our laboratory). These values were also substituted for missing values after surveillance was stopped, because otherwise there would be a bias for elevated values.
Patient characteristics recorded were age, sex, height, weight, body mass index (Table 1) , atherosclerotic risk factors, such as hypertension, total and HDLcholesterol, and smoking status (never smoked, quit smoking more than 5 years ago, current smoker; Table  2 ), and a history of diabetes including medications used to treat Type 2 diabetes. Metabolic parameters analysed were fasting glucose, oral glucose tolerance tests (75 g), and HbA 1c concentrations (Table 3) . Previous myocardial infarcts, a history of angina pectoris and medications to treat cardiovascular disease (nitrates, beta-blockers, Ca-antagonist, angiotensin-convertingenzyme inhibitors, digitalis; Table 4 ) were assessed as was the time of onset of pain or symptoms, the use of thrombolytic treatment, and complications of acute myocardial infarction (Table 5 ). All patients received standard clinical care including monitoring of vital functions on an intensive care unit during the initial hospital stay and thrombolytic treatment as indicated according to current guidelines [30, 31] . The occurrence of atrial and ventricular arrhythmia, especially ventricular fibrillation, was recorded as well as events necessitating resuscitation. all parameters were available from all study patients. Therefore, the number of patients that any particular mean value is based on is given in parentheses.
Life table analysis (survival curves) was performed according to Kaplan and Meier using software GraphPAD prism, version 2.1. Four groups of patients were analysed: (1) non-diabetic patients (including patients with impaired glucose tolerance), (2) patients in whom Type 2 diabetes was diagnosed on the occasion of the hospitalization due to acute myocardial infarction (newly diagnosed Type 2 diabetic patients), (3) previously known Type 2 diabetic patients on sulfonylurea treatment (all taking glibenclamide= glyburide), and (4) Type 2 diabetic patients not receiving sulfonylurea treatment. The latter group was heterogeneous and comprised (a) insulin treated patients, (b) patients treated with diet alone or diet in combination with (c) metformin, or (d) acarbose, or combinations of these treatment modalities (Table 3) . Given the fact that the reported in-hospital of myocardial infarction is higher in diabetic patients in general, and that the hypothesis to be tested was an influence of sulfonylureas on infarct size and its clinical impact, these two diabetic patient groups were compared with each other and with non-diabetic patients.
In-hospital mortality and all other categorical variables were also assessed with contingency table analysis (chi-square and Fisher's exact test). 95% confidence intervals were calculated using NCSS version 6.0 (J. Hintze, Kaysville, UT). Continuous variables were analysed using one-way analysis of variance. If significant differences between groups were detected (P<0·05), all three groups were compared by Student's t-test (unpaired). Significant differences were assumed if P-values were <0·05. 
Results
Patients
A total number of 602 patients with acute myocardial infarction was analysed. Three hundred and fifty-seven were non-diabetic patients . In 80, diabetes was detected at hospitalization. Of 175 patients previously known as Type 2 diabetic, 89 were treated without and 76 were treated with sulfonylurea compounds. The only sulfonylurea medication prescribed was glibenclamide (=glyburide).
Mortality
Survival analysis (Fig. 1 ) revealed a significant difference in in-hospital mortality between non-diabetic and previously known Type 2 diabetic patients (P=0·03). A higher proportion of Type 2 diabetic patients died, regardless of whether (32·9%; P=0·012 vs non-diabetic patients) or not (33·0%; P=0·025) they had been prescribed sulfonylurea compounds, in comparison to non-diabetic subjects (20·2%). Mortality in newly diagnosed Type 2 diabetic patients was intermediate (25·0%), and not significantly different from either the non-diabetic (P=0·64) and known Type 2 diabetic groups. In male patients, a similar pattern of in-hospital mortality was found, including a significant difference in mortality in previously known Type 2 diabetic patients vs non-diabetic patients, but a lack of significant difference between previously diagnosed Type 2 diabetic patients with and without sulfonylurea treatment (P=1·00). In women, there was a similar trend, but differences were not significant due to the small numbers (Table 6) . 
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Creatine kinase responses
Serum creatine kinase and creatine kinase MB increments in all patient groups followed a similar pattern with a peak approximately 24 h after hospital admission, and a return to baseline values after 3-6 days. Repeated measures analysis of variance revealed a significant interaction of group assignment and time (P<0·01; Fig.  2 ). However, only during the peak of creatine kinase (creatine kinase MB ) increments, did a cross-sectional one-way ANOVA approach significance (P-values 0·07 and 0·08 for creatine kinase and creatine kinase MB activities, respectively, at 24 h). Therefore, a clear difference could not be described. A trend towards smaller creatine kinase (and creatine kinase MB ) increments in previously known Type 2 diabetic patients, however, was there, with no difference whether the patients had received glibenclamide treatment or not.
Patient characteristics
Diabetic patients as a whole were older than nondiabetic patients (Table 1) . Previously known diabetic patients on sulfonylurea treatment were characterized by a higher proportion of female patients (significant vs non-diabetic patients). There was no difference in the degree of obesity. Hypertension was more frequent in previously known Type 2 diabetic patients, no matter whether treated with or without sulfonylureas ( Table 2) . There was a marked reduction in the proportion of patients smoking in all diabetic patients groups ( Table 2) . Previously known diabetic patients on sulfonylurea treatment had lower HDL-and LDL cholesterol concentrations (significant vs non-diabetic patients).
Fasting glucose concentrations were higher in all diabetic patient groups in comparison to non-diabetic patients, as were glycated haemoglobin concentrations (Table 3) . Previously known Type 2 diabetic patients on sulfonylurea treatment had higher fasting glucose (165 83 vs 151 74 mg . dl 1 ) and glycated haemoglobin (8·4 1·8 vs 7·7 1·3%) than previously known Type 2 diabetic patients treated with diet and/or other medication (Table 3) . A higher proportion of previously known diabetic patients had previous myocardial infarcts, and had been prescribed nitrates, calcium channel blockers, ACE inhibitors, digitalis, and diuretics more often (Table 4) . Angina pectoris was reported at least as often in diabetic as compared to non-diabetic patients (Table 4) . Diabetic patients were less likely to receive thrombolytic treatment, although the duration of symptoms was similar for all groups (Table 5 ). There were no major differences in the location of the myocardial infarct, or in the necessity for resuscitation or defibrillation between all groups studied (Table 5 ). In survivors, previously known diabetic patients were treated in hospital for a significantly longer period (Table 5) .
Discussion
Previous examinations have uniformly pointed to the increased early and late mortality after acute myocardial infarction in diabetic (including Type 2 diabetic) patients [20] [21] [22] . This has been attributed, for example, to 
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more widespread coronary disease and the inability of non-infarcted myocardium to respond with increased contractility [21] . The present study suggests that in unselected patients admitted to a maximum care academic hospital, in-hospital mortality is not higher in Type 2 diabetic patients treated with sulfonylurea drugs, in comparison to a similar group of previously diagnosed Type 2 diabetic patients, who at the time of myocardial infarction received treatment with diet, metformin, acarbose, insulin, or a combination of these agents (Fig. 1, Table  6 ). The sulfonylurea medication prescribed to all the patients in our study was glibenclamide (=glyburide), and its use was not associated with a higher risk of not surviving an acute myocardial infarction when compared to a group of Type 2 diabetic patients on other treatments (Fig. 1, Table 6 ).
Not surprisingly, all previously known Type 2 diabetic patients, no matter whether treated with diet alone, sulfonylurea drugs, other oral agents or insulin were characterized by an in-hospital mortality rate substantially (and certainly significantly) different from that in non-diabetic patients, the relative risk of dying being well within the previously reported range [20] [21] [22] 23] . AB=interaction between group and time). ANOVA performed to compare all groups of patients at individual time points failed to detect significant differences. A trend was seen after 24 h creatine kinase: P=0·07; creatine kinase MB ; P=0·09). =non-diabetic subjects; =newly diagnosed diabetics; =minus glibenclamide; =plus glibenclamide.
Thrombolytic treatment was used significantly less often in all Type 2 diabetic patients groups (Table 5 ). This may have contributed to the difference in survival (Fig. 1, Table 6 ).
Although the group of Type 2 diabetic patients treated with diet, metformin, acarbose, insulin was heterogeneous, it turned out to be very similar regarding patient characteristics that might have an influence on the risk not to survive an acute myocardial infarction, namely age, sex, smoking status, degree of overweight and hypercholesterolemia (Tables 1-5 ). Furthermore, there was no significant difference in the choice of treatment (thrombolysis, beta-blockers etc., Tables 4  and 5 ) between the two previously known diabetic groups, although differences existed between diabetic and non-diabetic patients (Tables 4 and 5 ). Therefore, it appears that potential effects of sulfonylurea drugs are not masked by differences in patient characteristics.
The present observation is not in line with UGDP data demonstrating at least a tendency for enhanced rather than lowered cardiovascular mortality in Type 2 diabetic patients randomized to tolbutamide treatment [1] . However, the manner in which these findings were reported does not differentiate between myocardial infarctions occurring more often in tolbutamide-treated patients than in patients not treated with this drug from an increased case-fatality rate in the face of an unchanged incidence of myocardial infarction. The latter would not be supported by our present data.
Our findings differ from those described by Rytter et al. (1985) [23] . They reported a higher 'early' mortality in tablet-treated patients with Type 2 diabetes (50%; n=54) than in those treated with insulin (9%; n=11) or diet alone 25%; n=8). In that study, however, no information was given on the type of tablet treatment. A recent large study from Australia [33] however, did not find an influence of sulfonylurea treatment on survival after myocardial infarction. This study has only been presented as an abstract, so that details cannot be compared. Even more recently, the survival of diabetic patients on different antidiabetic treatment modalities after myocardial infarction was compared and found not to be different, in small patient groups [34] . On the other hand, intervention studies in patients with impaired oral glucose tolerance demonstrated that tolbutamide treatment not only lowered the risk of progressing to an overt diabetic state, but was also associated with the lowest risk of cardiovascular mortality (in comparison to placebo and/or lifestyle interventions) [35] . Sulfonylureas, by interfering with ischaemic preconditioning, may in principle cause greater myocardial necroses, with the consequence of left ventricular failure, which has often been described as a typical clinical complication of myocardial infarction in diabetic patients [21, 23] . The occurrence of left heart failure has not been examined in respect of different antidiabetic drugs. Larger myocardial infarcts would most likely lead to increase creatine kinase and creatine kinase MB increments [26] . Our data (Fig. 2) , in line with previous reports [32, 36] , demonstrate a tendency towards lower creatine kinase and creatine kinase MB increments in previously known diabetic patients, regardless of the type of antidiabetic treatment. A possible explanation is that the extent and type of coronary vessel stenoses and occlusions may have differed between non-diabetic patients and the two diabetic groups [21, 37] . Assuming more diffuse coronary atherosclerosis, as indicated by a higher proportion of two-and three-vessel disease, and more distal critical stenoses, less myocardium would depend on the occluded vessel in the typical Type 2 diabetic patient. This may lower the creatine kinase increments following occlusion (Fig. 2) .
A similar number of patients have reported preinfarction angina in both diabetic patient groups (Table  4) . Hypothetically, this may support a similar degree of ischaemic preconditioning in all patient groups prior to acute myocardial infarction. The exact temporal relationship, however, cannot be ascertained due to the retrospective nature of our analysis. Ischaemic preconditioning only protects from ischaemic damaged during a period of 6-12 h [38] . The reduction of ventricular arrhythmias is reported as a beneficial effect of sulfonylureas. This antiarrhythmic effectiveness might be related to its locking action on the ATP-dependent potassium channel, with consequent attenuation of the efflux of potassium induced by ischemia [17] [18] [19] . Our data do not support this hypothesis. There are identical rates in ventricular fibrillation and resuscitation (Table 5 ) among our patient groups.
What might be the shortcomings of a retrospective analysis of non-diabetic and diabetic patients suffering myocardial infarction? First, underreporting of the use of sulfonylurea drugs may occur, which could have levelled out the differences between the groups. On the other hand, non-compliance may have occurred in patients who were prescribed sulfonylurea drugs. Again, the consequence would be a smaller rather than a larger difference in the outcome measures due to misclassification of patients. Therefore, the influence of sulfonylurea drugs on in-hospital mortality may have been underestimated. Thus, the recently reported benefit of treating Type 2 diabetic patients with acute myocardial infarction with insulin (rather than continuing on antidiabetic tablets) [39] may, in part, be based on the effect of withdrawing sulfonylureas. We did not use such a regime. Treatment of the diabetes mellitus followed accepted recommendations [30] It could be argued that randomized, prospective studies with patients allocated to sulfonylureas or alternative treatments could better answer the questions asked by the present analysis. In 1998 the UKPDS [40] , which compared the effects of intensive blood-glucose control with either sulfonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with Type 2 diabetes in a randomized controlled trial, was published. In this study no differences in the rates of sudden death, fatal and non-fatal myocardial infarction between participants assigned to chlorpropamide, glibenclamide
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or insulin were found. Such studies, however, must allow treatment to be changed if the treatment goals have not been achieved. Any intention-to-treat analysis would assign outcomes to the initially chosen treatment arm. Since the known mechanisms linking sulfonylurea treatment to cardiovascular complication depend on the recent administration and presence of glibenclamide in the circulation, this type of study appears less suitable to answer the questions asked. Furthermore, the UKPDS included only newly diagnosed, relatively young Type 2 diabetic patients, whereas the majority of cardiovascular complication may be expected to occur in elderly diabetic patients with a longer duration of the disease like those examined in the present study ( Table 1 ).
The older age of patients and the present, unselected study cohort probably is responsible for the overall high in-hospital mortality observed after acute myocardial infarction (Fig. 1, Table 6 ). The numbers are higher than those reported in randomized trials of anticoagulant and/or thrombolytic treatment [26, 41] , but patient selection (e.g. by age) was quite vigorous in these studies, whereas a non-selected cohort of successive patients with acute myocardial infarction was studied in the present analysis. In comparison to reported figures from other non-selected cohorts, in-hospital mortality was well within the typical mid-European range of values [42] . In principle, it may be conceivable that more diabetics treated with sulphonylureas die before admission to a hospital compared to patients treated with insulin. Nearly 50% of all patients suffering acute myocardial infarction do not reach hospital [42] . To our knowledge, no data concerning subgroups of patients treated with different antidiabetics are available.
In conclusion, no higher in-hospital mortality was demonstrated in Type 2 diabetic patients receiving sulfonylurea drugs (glibenclamide), when compared to Type 2 diabetic patients not taking sulfonylureas. There was, however, greater in-hospital mortality for all previously diagnosed Type 2 diabetic patients, in comparison to non-diabetic patients. A cardiovascular risk caused by an antidiabetic medication including glibenclamide in patients suffering acute myocardial infarction is not supported by the present results.
